MedPath

Oxybutynin

Generic Name
Oxybutynin
Brand Names
Ditropan, Gelnique, Kentera, Oxytrol, Kentera (previously Oxybutynin Nicobrand)
Drug Type
Small Molecule
Chemical Formula
C22H31NO3
CAS Number
5633-20-5
Unique Ingredient Identifier
K9P6MC7092

Overview

Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life. Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975. This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.

Background

Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life. Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975. This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.

Indication

Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms. On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.

Associated Conditions

  • Bladder Spasms
  • Detrusor Hyperreflexia
  • Overactive Bladder Syndrome (OABS)

FDA Approved Products

Oxybutynin Chloride Extended Release
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/06/28
NDC:62175-270
Oxybutynin Chloride Extended Release
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:15 mg in 1 1
Approved: 2023/06/28
NDC:62175-272
Oxybutynin Chloride Extended Release
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/06/28
NDC:62175-271
oxybutynin chloride
Manufacturer:PD-Rx Pharmaceuticals, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/06/16
NDC:72789-049
Oxybutynin Chloride Extended Release
Manufacturer:PD-Rx Pharmaceuticals, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/09/19
NDC:43063-790

Singapore Approved Products

OBUTIN TABLETS 5 mg
Manufacturer:HANLIM PHARMACEUTICAL CO LTD
Form:TABLET
Strength:5 mg
Online:Yes
Approved: 1999/11/04
Approval:SIN11215P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath